Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Routine +

Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

Eupraxia Durability Data Validates Lead Candidate, Yet Phase 2b Timing Shifts to Q4

By The Northwire Desk — AI Analysis Apr 21, 2026 · 07:00 EPRX · 9.9 EUPRAXIA PHARMACEUTICALS INC. J
Executive Summary
  • Date: April 21, 2026
  • Event: Clinical Trial Results (Phase 1b/2a RESOLVE Trial)
  • Key Finding: Positive nine-month (36-week) tissue health and symptom data from Cohort 9 (highest dose: 20 x 8 mg).
  • Efficacy: 66% clinical remission rate maintained from week 8 through week 36 in Cohort 9. Peak Eosinophil Count reduced by 72%.
  • Safety: No drug-related Serious Adverse Events (SAEs) or steroid side effects (candidiasis, adrenal insufficiency) across 31 patients (>230 patient-months).
  • Timeline Update: Phase 2b top-line data expected in Q4 2026 (previously indicated as Q3 2026 in March 2026 news).
Material Impact
  • Confirmation of Thesis: The data confirms the durability of EP-104GI, a critical requirement for a once-a-year treatment claim. This aligns with previous positive signals from January and March 2026 regarding tissue health and symptom response.
  • Incremental Nature: While robust, this is open-label Phase 1b/2a data. The market has already priced in significant optimism following the September 2025 selection of Cohort 9 for Phase 2b and the January/March clinical updates.
  • Timeline Shift: The shift of Phase 2b top-line data from Q3 2026 (March news) to Q4 2026 (April news) introduces a minor delay risk, potentially extending the period without definitive placebo-controlled proof.
  • Market Reaction Context: Following a significant rally from $4.84 (April 2025) to $12.50 (January 2026), the stock has corrected to ~$9.90. This news supports the current valuation but is unlikely to trigger a breakout without Phase 2b placebo-controlled results.
  • Verdict: The news is positive and reinforces safety/efficacy, but it is largely expected given the trajectory of previous announcements. It does not fundamentally alter the investment thesis established in late 2025.
EPRX · Price
Company Overview
  • Company: Eupraxia Pharmaceuticals Inc. (EPRX).
  • Focus: Development of novel therapies for gastrointestinal diseases using its Diffusphere™ platform.
  • Flagship Asset: EP-104GI, a topical corticosteroid (fluticasone propionate) delivered via endoscopic injection for Eosinophilic Esophagitis (EoE).
  • Mechanism: Designed to provide sustained release of fluticasone directly into the esophageal tissue, aiming for once-a-year dosing compared to daily oral/topical steroids.
  • Development Stage: Phase 1b/2a RESOLVE trial ongoing; Phase 2b randomized placebo-controlled trial recruiting.
Read the original news release →

More from EUPRAXIA PHARMACEUTICALS INC. J

May 12, 2026 · 17:00

Eupraxia Pharmaceuticals Secures H2 2028 Runway with Strong Clinical Data, But Phase 2b Catalyst Remains Key

Earnings May 06, 2026 · 07:00

Eupraxia Confirms Fibrosis Reversal in EoE, But Phase 2b Readout Remains Key Catalyst

Other May 05, 2026 · 07:00

Eupraxia Confirms Dose-Response in EoE Trial; Phase 2b Data Due Q4

Other Apr 22, 2026 · 07:00

Eupraxia Confirms Durable Efficacy and Safety Profile Ahead of Phase 2b Top-Line Readout

Other Mar 17, 2026 · 12:41

Eupraxia posts 24-week data in high-dose Resolve cohort

Other Mar 17, 2026 · 07:00

Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

Other